Current Oncology Reports

, Volume 14, Issue 6, pp 483–485

Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?

Invited Commentary

DOI: 10.1007/s11912-012-0263-7

Cite this article as:
Banerjee, S. & Kaye, S. Curr Oncol Rep (2012) 14: 483. doi:10.1007/s11912-012-0263-7


Ovarian cancer Poly(adenosine diphosphate ribose) polymerase inhibitors Survival End point Olaparib Bevacizumab 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Gynaecology Unit, The Royal Marsden NHS Foundation TrustLondonUK
  2. 2.Division of Clinical StudiesInstitute of Cancer ResearchLondonUK

Personalised recommendations